TMCnet News
Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung DiseaseWARREN, N.J., May 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will host a Key Opinion Leader (KOL) lunch meeting focused on Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) on Wednesday, May 29, 2019, from 12:00 – 1:30 PM ET in New York City. The meeting will feature a presentation by Steven D. Nathan, M.D., F.C.C.P., from Inova Fairfax Hospital, who will discuss the current treatment landscape and unmet medical need for patients with PH-ILD. There are currently no approved therapies for PH-ILD, which is characterized by progressive and substantial worsening of outcomes such as physical activity levels, quality of life and life expectancy. Dr. Nathan will be available to answer questions following the meeting. Bellerophon's management team will also provide an overview of the Company’s ongoing clinical development program with its proprietary INOpulse® therapy, which is designed to deliver pharmaceutical-grade nitric oxide in a targeted fashion to the well-ventilated sections of the patient's lung. Bellerophon will focus on its ongoing Phase 2/3 clinical study to progress INOpulse for the treatment of PH-ILD. The Company previously reported positive results from Cohort 1 in which subjects on active treatment demonstrated a clinically and statistically significant improvement of 34% in moderate to vigorous physical activity (MVPA) as compared to subjects on placebo, as well as improvements in overall activity, oxygen saturation and additional functional measures. Bellerophon has agreement with the U.S. Food and Drug Administration (FDA) on a regulatory pathway, including the use of MVPA as the study’s primary endpoint, and expects to complete Cohort 2 and initiate the pivotal Phase 3 trial in the second half of 2019. Dr. Nathan is Medical Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital. He also is Professor of Medicine at Virginia Commonwealth University Inova Campus. Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. The author of more than 380 publications, Dr. Nathan has written original research manuscripts, abstracts, reviews, book chapters and a book on idiopathic pulmonary fibrosis (IPF), which he coedited. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including FDA advisory boards, as well as steering committees for clinical trials in IPF and pulmonary hypertension, where he hasalso served as chair. He is also chairperson of Pilot for IPF, an international educational initiative for pulmonary fibrosis. Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. He has delivered talks and been chairperson of numerous sessions at many national and international conferences. This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast. About Bellerophon Forward-looking Statements
|